Third Rock Ventures V, L.P. 4
4 · Rapport Therapeutics, Inc. · Filed Apr 21, 2026
Research Summary
AI-generated summary of this filing
Rapport Therapeutics (RAPP) 10% Owner Sells 426,005 Shares
What Happened
- Third Rock Ventures V, L.P. (a reported 10% owner of Rapport Therapeutics, ticker RAPP) sold 426,005 shares on April 17, 2026. The sales were effected at a weighted-average price of $40.32 per share for total proceeds of $17,175,244. This was a sale (not a purchase) and therefore generally a liquidity event rather than an indicated vote of confidence in the company.
Key Details
- Transaction date and prices: April 17, 2026; shares sold in multiple trades at prices ranging from $40.00 to $40.79; weighted-average price $40.32. (Footnote: reporting person can provide per-trade price breakdown on request.)
- Total value: $17,175,244.
- Shares owned after transaction: not specified in the excerpt of the filing provided.
- Plan/authority: Sales were made pursuant to a Rule 10b5‑1 trading plan adopted November 21, 2025 (pre-arranged plan).
- Ownership structure/disclaimer: Shares are directly held by Third Rock Ventures V, L.P.; related general partner entities disclaim beneficial ownership except to the extent of pecuniary interest. Related Third Rock entities and GP entities also disclaim being part of a Section 13(d) group.
- Filing timeliness: The Form 4 was filed April 21, 2026 for the April 17 transaction. Form 4s are generally required within two business days of the transaction, so this filing appears to have been submitted after that typical window.
Context
- This transaction was an institutional sale by a 10% owner and was executed under a Rule 10b5‑1 plan (a pre-scheduled trading arrangement). Such sales are commonly scheduled for liquidity and do not, by themselves, indicate the insider’s current view of company prospects.
Insider Transaction Report
Form 4
Third Rock Ventures V, L.P.
10% Owner
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-04-17$40.32/sh−426,005$17,175,244→ 6,709,228 total
Holdings
- 969,218(indirect: By Third Rock Ventures VI, L.P.)
Common Stock
[F4]
Footnotes (4)
- [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 21, 2025, previously adopted by the Reporting Person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
- [F3]These shares are directly held by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
- [F4]The shares are held directly by Third Rock Ventures VI, L.P. ("TRV VI"). The general partner of TRV VI is Third Rock Ventures GP VI, L.P. ("TRV GP VI"). The general partner of TRV GP VI is TRV GP VI, LLC ("TRV GP VI LLC"). Each of TRV GP VI, and TRV GP VI LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between any TRV V related parties and any TRV VI related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.